Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury

NCT04819685 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2021-03-29

No results posted yet for this study

Summary

A total of 520 cases will be randomly divided into Kang Fu Pen (liquid dressing) enema intervention group (experimental group) and non-enema intervention group (control group), according to the ratio of 1:1.

Conditions

Interventions

DRUG

KANG FU PEN

FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER
  • Chinese PLA General Hospital

    collaborator OTHER
  • Peking University Third Hospital

    collaborator OTHER
  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER
  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER
  • Sun Yat-sen University

    collaborator OTHER
  • Jilin Provincial Tumor Hospital

    collaborator OTHER
  • Fudan University

    collaborator OTHER
  • Shandong Cancer Hospital and Institute

    collaborator OTHER
  • The First Affiliated Hospital of Air Force Medicial University

    collaborator OTHER
  • Guizhou Cancer Hospital (The Affiliated Cancer Hospital of Guizhou Medical University)

    collaborator UNKNOWN
  • Zhejiang Cancer Hospital

    collaborator OTHER
  • Xiangya Hospital of Central South University

    collaborator OTHER
  • Henan Cancer Hospital

    collaborator OTHER_GOV
  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-03-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04819685 on ClinicalTrials.gov